Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

The development of therapeutic cancer vaccines as a means to generate immune reactivity
against tumors has been explored since the early discovery of tumor-specific antigens by …

Background Malaria transmission-blocking vaccines target mosquito-stage parasites and
will support elimination programmes. Gamete vaccine Pfs230D1-EPA/Alhydrogel induced …

BACKGROUND Vaccines that block human-to-mosquito Plasmodium transmission are
needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for …

Pfs25 is a malaria transmission-blocking vaccine antigen candidate, but its apparently
limited immunogenicity in humans has hindered clinical development. Here, we show that …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by
targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in …

Summary Background Pfs25H-EPA is a protein-protein conjugate transmission-blocking
vaccine against Plasmodium falciparum that is safe and induces functional antibodies in …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

Abstract The Malaria Vaccine Symposium occurred at Johns Hopkins University in
Baltimore, MD, USA on April 25th, 2017, coinciding with World Malaria Day and the WHO …